Using mass spectrometric analyses, we found that most elevated proteins in Ki8751-treated cancers were all mitochondrial proteins, namely NDFIP1, CLK1, and TEFM, suggesting that Ki8751 treatments may enhance mitochondrial biogenesis of breast cancer cells. This evidence concerns the gene CLK1 and breast cancer.